Related Experiment Video
Updated: Aug 14, 2026
08:25
Transverse Aortic Constriction in Mice
Published on: April 21, 2010
PKC-beta is not necessary for cardiac hypertrophy
B B Roman1, D L Geenen, M Leitges
1Section of Cardiology, Department of Medicine, University of Illinois at Chicago, Illinois 60612, USA. broman@uic.edu
Summary
Ablating protein kinase C-beta (PKC-beta) did not prevent cardiac hypertrophy in mice. These findings indicate that the PKC-beta pathway is not essential for developing or attenuating cardiac hypertrophy.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Physiology
Background:
- Protein kinase C-beta (PKC-beta) activation is linked to pathological cardiac hypertrophy in human and rodent models.
- Targeting the PKC-beta pathway is a potential strategy to prevent or reverse cardiac hypertrophy.
Purpose of the Study:
- To investigate the necessity of PKC-beta in the development of cardiac hypertrophy.
- To determine if PKC-beta deficiency attenuates the hypertrophic response to stimuli.
Main Methods:
- Studied gene knockout (KO) mice lacking the PKC-beta gene.
- Assessed cardiac hypertrophy using phenylephrine (Phe) infusion and aortic banding (AoB) models.
- Measured heart weight-to-body weight ratio and atrial natriuretic factor mRNA levels.
Main Results:
- No significant differences in baseline hemodynamics or other PKC isoform expression between KO and control mice.
- PKC-beta KO mice exhibited cardiac hypertrophy in response to both Phe and AoB stimuli, similar to control animals.
- Ventricular atrial natriuretic factor mRNA was upregulated in KO animals, indicating a hypertrophic response.
Conclusions:
- PKC-beta expression is not required for the development of cardiac hypertrophy.
- The absence of PKC-beta does not attenuate the cardiac hypertrophic response to pharmacological or mechanical stress.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...